Finch Therapeutics to Participate in the Chardan Metagenomics and Microbiome Medicines Summit
23 févr. 2022 07h00 HE
|
Finch Therapeutics Group, Inc.
SOMERVILLE, Mass., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its...
Finch Therapeutics Announces Additions to Senior Leadership Team
10 févr. 2022 07h00 HE
|
Finch Therapeutics Group, Inc.
Bryan Gillis, MBA, appointed Chief Technology OfficerAlka Batycky, PhD, appointed Chief Development OfficerHoward Franklin, MD, MBA, appointed Senior Vice President, Late-Stage Development and GI...
Finch Therapeutics Further Strengthens Patent Portfolio with Two New U.S. Patents Granted for FIN-211, an Investigational Microbiome Therapeutic in Development for Autism Spectrum Disorder
06 janv. 2022 07h00 HE
|
Finch Therapeutics Group, Inc.
SOMERVILLE, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its...
Finch Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference and H.C. Wainwright BioConnect Conference
04 janv. 2022 07h00 HE
|
Finch Therapeutics Group, Inc.
SOMERVILLE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its...
Finch Therapeutics Appoints Joseph Vittiglio, JD, as Chief Business and Legal Officer
20 déc. 2021 07h00 HE
|
Finch Therapeutics Group, Inc.
SOMERVILLE, Mass., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its...
Finch Therapeutics to Participate in Upcoming Investor Conferences
11 nov. 2021 07h00 HE
|
Finch Therapeutics Group, Inc.
SOMERVILLE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its...
Finch Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates
10 nov. 2021 07h05 HE
|
Finch Therapeutics Group, Inc.
New positive topline data from 132-participant PRISM-EXT Phase 2 open-label trial of CP101 in recurrent C. difficile infection (CDI) show 80.3% sustained clinical cure rate through 8 weeks, with a...
Finch Therapeutics Announces Transition of Chief Medical Officer
10 nov. 2021 07h00 HE
|
Finch Therapeutics Group, Inc.
Zain Kassam, MD, MPH to step down as Chief Medical Officer (CMO) and will serve as a special advisor to the companyDebra Silberg, MD, PhD to transition from clinical advisor to interim CMO ...
Finch Therapeutics Announces Positive Topline Results from PRISM-EXT Phase 2 Trial of CP101 for Prevention of Recurrent C. difficile Infection
09 nov. 2021 16h30 HE
|
Finch Therapeutics Group, Inc.
New data from 132-participant PRISM-EXT Phase 2 open-label trial show 80.3% sustained clinical cure rate through 8 weeks, with a similar rate maintained through 24 weeks and a safety profile...
Finch Therapeutics Presents Positive Data from PRISM3 Clinical Trial of CP101 for Recurrent C. difficile at American College of Gastroenterology Annual Scientific Meeting
25 oct. 2021 07h00 HE
|
Finch Therapeutics Group, Inc.
New data from PRISM3 Phase 2 trial show CP101 demonstrated statistically significant efficacy for prevention of recurrent C. difficile infection and a favorable safety profile through 24...